X

Drug Profile

Metaxalone - Primus Pharmaceuticals

Latest Information Update: 19 Apr 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Primus Pharmaceuticals
Class Benzene derivatives; Ethers; Muscle relaxants; Oxazolidinones; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Musculoskeletal disorders

Most Recent Events

12 Apr 2024 Chemical structure information added
10 Apr 2024 Primus Pharmaceuticals has pending patent application worldwide for Reduced dose metaxalone formulations
10 Jan 2024 The US FDA approves Metaxalone as an adjunctive treatment of Musculoskeletal pain in the USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com